Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Nutr Neurosci. 2015 May; 18(4):169-76.NN

Abstract

OBJECTIVES

Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of central nervous system and recent studies show that inflammatory processes are highly associated with neurodegeneration in the brain. The purpose of this study was to investigate the effect of coenzyme Q10 supplementation on inflammatory and anti-inflammatory markers in patients with MS.

METHODS

This randomized, double-blind, placebo-controlled clinical study was performed among 48 patients with relapsing-remitting MS. Subjects were randomly assigned to a placebo group (n = 24) or coenzyme Q10 (CoQ10)-supplemented group (500 mg/day, n = 24). The intervention was administered for 12 weeks. Peripheral blood samples were collected at baseline and after 12-week intervention, to measure inflammatory (tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and matrix metalloproteinase (MMP)-9) and anti-inflammatory (IL-4 and TGF-β) markers.

RESULTS

Forty-five patients completed the study. After 12 weeks of intervention, the TNF-α levels (P = 0.003) decreased significantly in the CoQ10 group. Subjects in the CoQ10 group had significantly lower IL-6 levels (P = 0.037), compared to the placebo group. CoQ10 supplementation also resulted in decreased serum levels of MMP-9 as compared to the placebo group (P = 0.011). However, CoQ10 supplementation did not alter the IL-4 and TGF-β levels (P = 0.16 and P = 0.81, respectively).

DISCUSSION

CoQ10 supplementation at a dosage of 500 mg appears to decrease the inflammatory markers (TNF-α, IL-6, and MMP-9) in patients with MS.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24621064

Citation

Sanoobar, Meisam, et al. "Coenzyme Q10 Supplementation Ameliorates Inflammatory Markers in Patients With Multiple Sclerosis: a Double Blind, Placebo, Controlled Randomized Clinical Trial." Nutritional Neuroscience, vol. 18, no. 4, 2015, pp. 169-76.
Sanoobar M, Eghtesadi S, Azimi A, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18(4):169-76.
Sanoobar, M., Eghtesadi, S., Azimi, A., Khalili, M., Khodadadi, B., Jazayeri, S., Gohari, M. R., & Aryaeian, N. (2015). Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutritional Neuroscience, 18(4), 169-76. https://doi.org/10.1179/1476830513Y.0000000106
Sanoobar M, et al. Coenzyme Q10 Supplementation Ameliorates Inflammatory Markers in Patients With Multiple Sclerosis: a Double Blind, Placebo, Controlled Randomized Clinical Trial. Nutr Neurosci. 2015;18(4):169-76. PubMed PMID: 24621064.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. AU - Sanoobar,Meisam, AU - Eghtesadi,Shahryar, AU - Azimi,Amirreza, AU - Khalili,Mohammad, AU - Khodadadi,Behnam, AU - Jazayeri,Shima, AU - Gohari,Mahmood Reza, AU - Aryaeian,Nahid, Y1 - 2014/01/10/ PY - 2014/3/14/entrez PY - 2014/3/14/pubmed PY - 2015/10/23/medline KW - Antioxidants KW - Coenzyme Q10 KW - Cytokines KW - IL-6 KW - Inflammation KW - MMP-9 KW - Multiple sclerosis KW - Randomized placebo-controlled trial KW - Supplementation KW - TGF-β KW - TNF-α SP - 169 EP - 76 JF - Nutritional neuroscience JO - Nutr Neurosci VL - 18 IS - 4 N2 - OBJECTIVES: Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of central nervous system and recent studies show that inflammatory processes are highly associated with neurodegeneration in the brain. The purpose of this study was to investigate the effect of coenzyme Q10 supplementation on inflammatory and anti-inflammatory markers in patients with MS. METHODS: This randomized, double-blind, placebo-controlled clinical study was performed among 48 patients with relapsing-remitting MS. Subjects were randomly assigned to a placebo group (n = 24) or coenzyme Q10 (CoQ10)-supplemented group (500 mg/day, n = 24). The intervention was administered for 12 weeks. Peripheral blood samples were collected at baseline and after 12-week intervention, to measure inflammatory (tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and matrix metalloproteinase (MMP)-9) and anti-inflammatory (IL-4 and TGF-β) markers. RESULTS: Forty-five patients completed the study. After 12 weeks of intervention, the TNF-α levels (P = 0.003) decreased significantly in the CoQ10 group. Subjects in the CoQ10 group had significantly lower IL-6 levels (P = 0.037), compared to the placebo group. CoQ10 supplementation also resulted in decreased serum levels of MMP-9 as compared to the placebo group (P = 0.011). However, CoQ10 supplementation did not alter the IL-4 and TGF-β levels (P = 0.16 and P = 0.81, respectively). DISCUSSION: CoQ10 supplementation at a dosage of 500 mg appears to decrease the inflammatory markers (TNF-α, IL-6, and MMP-9) in patients with MS. SN - 1476-8305 UR - https://www.unboundmedicine.com/medline/citation/24621064/Coenzyme_Q10_supplementation_ameliorates_inflammatory_markers_in_patients_with_multiple_sclerosis:_a_double_blind_placebo_controlled_randomized_clinical_trial_ L2 - http://www.tandfonline.com/doi/full/10.1179/1476830513Y.0000000106 DB - PRIME DP - Unbound Medicine ER -